[go: up one dir, main page]

AR087277A1 - Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos - Google Patents

Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos

Info

Publication number
AR087277A1
AR087277A1 ARP120102658A ARP120102658A AR087277A1 AR 087277 A1 AR087277 A1 AR 087277A1 AR P120102658 A ARP120102658 A AR P120102658A AR P120102658 A ARP120102658 A AR P120102658A AR 087277 A1 AR087277 A1 AR 087277A1
Authority
AR
Argentina
Prior art keywords
biodisponable
amorphy
compositions
methods
pharmaceutical composition
Prior art date
Application number
ARP120102658A
Other languages
English (en)
Inventor
Rodney D Vickery
Kevin J Stefanski
Ching Su
Michael J Chiang-Hageman
Balvinder S Vig
Seema Betigeri
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR087277A1 publication Critical patent/AR087277A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dispersiones amorfas sólidas que comprenden el compuesto I que tiene la fórmula (1) o sus estereoisómeros y uno o varios polímeros. Dispersiones sólidas amorfas biodisponibles del compuesto I que son inesperadamente estables en suspensión y en el estado sólido durante períodos prolongados que se pueden usar para formación de comprimidos.Reivindicación 9: La dispersión de acuerdo con la reivindicación 1, caracterizada porque el polímero es PVP. Reivindicación 10: La dispersión de acuerdo con la reivindicación 1, caracterizada porque el polímero es HPMC-AS.
ARP120102658A 2011-07-21 2012-07-20 Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos AR087277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161510160P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
AR087277A1 true AR087277A1 (es) 2014-03-12

Family

ID=46604569

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102658A AR087277A1 (es) 2011-07-21 2012-07-20 Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos

Country Status (5)

Country Link
US (1) US9095585B2 (es)
EP (1) EP2734190A1 (es)
AR (1) AR087277A1 (es)
TW (1) TW201311240A (es)
WO (1) WO2013013114A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
CN105012242A (zh) * 2015-07-21 2015-11-04 南京中医药大学 一种厚朴酚或和厚朴酚或两者混合物固体分散体及其热熔挤出制备方法
US9981041B2 (en) 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray
MX2022003150A (es) 2019-09-18 2022-04-06 Bristol Myers Squibb Co Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA868963B (en) 1985-11-27 1988-07-27 Syntex Inc Amorphous anthelmintic benzimidazole derivatives
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
BR0313428A (pt) * 2002-08-12 2005-06-28 Pfizer Prod Inc Composições farmacêuticas de drogas semi-ordenados e polìmeros
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions

Also Published As

Publication number Publication date
WO2013013114A1 (en) 2013-01-24
TW201311240A (zh) 2013-03-16
US20140163071A1 (en) 2014-06-12
EP2734190A1 (en) 2014-05-28
US9095585B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
JOP20180103A1 (ar) مركب صيدلاني
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
UY35510A (es) ?composiciones y métodos para mejorar la estabilidad microbiana?.
EA201500652A1 (ru) Дифторметилникотиновые инданилкарбоксамиды
UA117362C2 (uk) Модулятори метил-модифікуючих ферментів, композиції та їх застосування
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
AR086042A1 (es) Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
PE20151335A1 (es) Composicion farmaceutica con biodisponibilidad mejorada
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
NZ723198A (en) Anthelmintic compounds and compositions and methods of using thereof
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201390198A1 (ru) Гетероциклическое соединение
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
MX367561B (es) Composicion cosmetica.
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
IN2014DN08637A (es)
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure